James V. Freeman

• Alan Enriquez
• Alexandra Lansky
• Amarnath Annapureddy
• Benjamin Rodwin
• Bradley Kay
• Catherine Mezzacappa
• Cesar Caraballo-Cordovez
• Daniel Jacoby
• Edward J Miller
• Erica Spatz
• Harlan Krumholz
• James Hummel
• Jeptha Curtis
• John K Forrest
• John Kadado
• Joseph Akar
• Joseph Ross
• Judith Meadows
• Kamil Faridi
• Karl Minges
• Karthik Murugiah
• Katherine Clark
• Kim Germaine Emiel Smolderen
• Louise Gambone
• Lucy Pereira
• Lynda Rosenfeld
• Maxwell Eder
• Michael Fuery
• Nihar Desai
• Rachel Dreyer
• Robert McNamara
• Rohan Khera
• Samuel Reinhardt
• Sarah Zimmerman
• Shu-Xia Li
• Sounok Sen
• Suveen Angraal
• Tariq Ahmad
• Yongfei Wang
• Zhenqiu Lin

Arrhythmias, Cardiac; Atrial Flutter; Cardiology; Heart Arrest; Quality of Health Care; Ventricular Fibrillation; Defibrillators, Implantable; Health Care Quality, Access, and Evaluation

Cardiovascular Diseases; Health Care Quality, Efficiency

• Frailty and associated outcomes in patients undergoing percutaneous left atrial appendage occlusion: findings from the NCDR LAAO registryDarden D, Bilal Munir M, Zimmerman S, Eskander M, Pothineni N, Gopinathannair R, Kabra R, Lakkireddy D, Duong T, Han F, Freeman J, Hsu J. Frailty and associated outcomes in patients undergoing percutaneous left atrial appendage occlusion: findings from the NCDR LAAO registry. Journal Of Interventional Cardiac Electrophysiology 2023, 1-11. PMID: 37858000, DOI: 10.1007/s10840-023-01662-1.
• Intracardiac vs Transesophageal Echocardiography for Left Atrial Appendage Occlusion With Watchman FLX in the U.S.Ferro E, Alkhouli M, Nair D, Kapadia S, Hsu J, Gibson D, Freeman J, Price M, Roy K, Allocco D, Yeh R, Piccini J. Intracardiac vs Transesophageal Echocardiography for Left Atrial Appendage Occlusion With Watchman FLX in the U.S. JACC Clinical Electrophysiology 2023, 9: 2587-2599. PMID: 37831030, DOI: 10.1016/j.jacep.2023.08.004.
• TCT-33 Racial Disparities in the Utilization and Outcomes of LAA Occlusion Using Watchman FLX: A SURPASS analysis of the NCDR LAAO RegistryAlli S, Garg J, Kapadia S, Yeh R, Price M, Piccini J, Nair D, Hsu J, Christen T, Allocco D, Freeman J. TCT-33 Racial Disparities in the Utilization and Outcomes of LAA Occlusion Using Watchman FLX: A SURPASS analysis of the NCDR LAAO Registry. Journal Of The American College Of Cardiology 2023, 82: b14. DOI: 10.1016/j.jacc.2023.09.038.
• Left ventricular lead implantation failure in an unselected nationwide cohortFriedman D, Qin L, Freeman J, Singh J, Curtis J, Piccini J, Al-Khatib S, Jackson K. Left ventricular lead implantation failure in an unselected nationwide cohort. Heart Rhythm 2023, 20: 1420-1428. PMID: 37406870, DOI: 10.1016/j.hrthm.2023.06.023.
• Impact of Preprocedure Imaging for Left Atrial Appendage Occlusion Insights From the NCDR LAAO RegistryClarke J, Higgins A, Wang Y, Faridi K, Curtis J, Freeman J, Friedman D. Impact of Preprocedure Imaging for Left Atrial Appendage Occlusion Insights From the NCDR LAAO Registry. JACC Cardiovascular Interventions 2023, 16: 1317-1328. PMID: 37316143, DOI: 10.1016/j.jcin.2023.05.008.
• In-hospital complications associated with pulmonary vein isolation with adjunctive lesions: the NCDR AFib Ablation RegistryDarden D, Aldaas O, Du C, Munir M, Feld G, Pothineni N, Gopinathannair R, Lakkireddy D, Curtis J, Freeman J, Akar J, Hsu J. In-hospital complications associated with pulmonary vein isolation with adjunctive lesions: the NCDR AFib Ablation Registry. EP Europace 2023, 25: euad124. PMID: 37184436, PMCID: PMC10228609, DOI: 10.1093/europace/euad124.
• CE-452771-4 OUTCOMES WITH DIFFERENT POSTPROCEDURAL ANTITHROMBOTIC THERAPY REGIMENS FOLLOWING LEFT ATRIAL APPENDAGE OCCLUSIONFreeman J, Hsu J, Kapadia S, Yeh R, Price M, Nair D, Christen T, Allocco D, Gibson D. CE-452771-4 OUTCOMES WITH DIFFERENT POSTPROCEDURAL ANTITHROMBOTIC THERAPY REGIMENS FOLLOWING LEFT ATRIAL APPENDAGE OCCLUSION. Heart Rhythm 2023, 20: s36-s37. DOI: 10.1016/j.hrthm.2023.03.272.
• CE-452771-3 LEFT ATRIAL APPENDAGE OCCLUSION WITH THE WATCHMAN FLX AND CONCOMITANT CATHETER ABLATION PROCEDURESPiccini J, Kapadia S, Yeh R, Price M, Hsu J, Freeman J, Gibson D, Christen T, Allocco D, Nair D. CE-452771-3 LEFT ATRIAL APPENDAGE OCCLUSION WITH THE WATCHMAN FLX AND CONCOMITANT CATHETER ABLATION PROCEDURES. Heart Rhythm 2023, 20: s35-s36. DOI: 10.1016/j.hrthm.2023.03.271.
• SCAI/HRS Expert Consensus Statement on Transcatheter Left Atrial Appendage ClosureSaw J, Holmes D, Cavalcante J, Freeman J, Goldsweig A, Kavinsky C, Moussa I, Munger T, Price M, Reisman M, Sherwood M, Turi Z, Wang D, Whisenant B. SCAI/HRS Expert Consensus Statement on Transcatheter Left Atrial Appendage Closure. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 100577. DOI: 10.1016/j.jscai.2022.100577.
• Watchman device migration and embolization: A report from the NCDR LAAO RegistryFriedman D, Freeman J, Zimmerman S, Tan Z, Pereira L, Faridi K, Curtis J. Watchman device migration and embolization: A report from the NCDR LAAO Registry. Journal Of Cardiovascular Electrophysiology 2023, 34: 1192-1195. PMID: 37078339, PMCID: PMC10290479, DOI: 10.1111/jce.15909.
• SCAI/HRS Expert Consensus Statement on Transcatheter Left Atrial Appendage ClosureSaw J, Holmes D, Cavalcante J, Freeman J, Goldsweig A, Kavinsky C, Moussa I, Munger T, Price M, Reisman M, Sherwood M, Turi Z, Wang D, Whisenant B. SCAI/HRS Expert Consensus Statement on Transcatheter Left Atrial Appendage Closure. JACC Cardiovascular Interventions 2023, 16: 1384-1400. PMID: 36990858, DOI: 10.1016/j.jcin.2023.01.011.
• SCAI/HRS expert consensus statement on transcatheter left atrial appendage closureSaw J, Holmes D, Cavalcante J, Freeman J, Goldsweig A, Kavinsky C, Moussa I, Munger T, Price M, Reisman M, Sherwood M, Turi Z, Wang D, Whisenant B. SCAI/HRS expert consensus statement on transcatheter left atrial appendage closure. Heart Rhythm 2023, 20: e1-e16. PMID: 36990925, DOI: 10.1016/j.hrthm.2023.01.007.
• Variation in hospital use of cardiac resynchronization therapy-defibrillator among eligible patients and association with clinical outcomesChui P, Lan Z, Freeman J, Enriquez A, Khera R, Akar J, Masoudi F, Ong E, Curtis J. Variation in hospital use of cardiac resynchronization therapy-defibrillator among eligible patients and association with clinical outcomes. Heart Rhythm 2023, 20: 1000-1008. PMID: 36963741, DOI: 10.1016/j.hrthm.2023.03.022.
• NOVEL 5-POINT FRAILTY SCALE IN PATIENTS UNDERGOING PERCUTANEOUS LEFT ATRIAL APPENDAGE OCCLUSION: INSIGHTS FROM THE NCDR LAAO REGISTRYDarden D, Zimmerman S, Munir M, Eskander M, Duong T, Pothineni N, Gopinathannair R, Lakkireddy D, Han F, Reeves R, Curtis J, Freeman J, Hsu J. NOVEL 5-POINT FRAILTY SCALE IN PATIENTS UNDERGOING PERCUTANEOUS LEFT ATRIAL APPENDAGE OCCLUSION: INSIGHTS FROM THE NCDR LAAO REGISTRY. Journal Of The American College Of Cardiology 2023, 81: 45. DOI: 10.1016/s0735-1097(23)00489-8.
• INTRACARDIAC VS TRANSESOPHAGEAL ECHOCARDIOGRAPHY USE FOR LEFT ATRIAL APPENDAGE OCCLUSION WITH WATCHMAN FLX: COMPARATIVE EFFECTIVENESS AND SAFETY AT 45 DAYS IN 40,738 PATIENTS FROM THE NCDR LAAO REGISTRYFerro E, Yeh R, Kapadia S, Hsu J, Gibson D, Freeman J, Price M, Alkhouli M, Roy K, Allocco D, Piccini J. INTRACARDIAC VS TRANSESOPHAGEAL ECHOCARDIOGRAPHY USE FOR LEFT ATRIAL APPENDAGE OCCLUSION WITH WATCHMAN FLX: COMPARATIVE EFFECTIVENESS AND SAFETY AT 45 DAYS IN 40,738 PATIENTS FROM THE NCDR LAAO REGISTRY. Journal Of The American College Of Cardiology 2023, 81: 90. DOI: 10.1016/s0735-1097(23)00534-x.
• PROCEDURE VOLUME AND OUTCOMES WITH WATCHMAN LEFT ATRIAL APPENDAGE CLOSURE: A REPORT FROM THE NCDR LAAO REGISTRYFriedman D, Du C, Lin Z, Vemulapalli S, Kosinski A, Piccini J, Pereira L, Minges K, Masoudi F, Faridi K, Curtis J, Freeman J. PROCEDURE VOLUME AND OUTCOMES WITH WATCHMAN LEFT ATRIAL APPENDAGE CLOSURE: A REPORT FROM THE NCDR LAAO REGISTRY. Journal Of The American College Of Cardiology 2023, 81: 48. DOI: 10.1016/s0735-1097(23)00492-8.
• Initial Findings From the National Cardiovascular Data Registry of Atrial Fibrillation Ablation ProceduresHsu J, Darden D, Du C, Marine J, Nichols S, Marcus G, Natale A, Noseworthy P, Selzman K, Varosy P, Masoudi F, Freeman J, Curtis J, Akar J, Kowey P. Initial Findings From the National Cardiovascular Data Registry of Atrial Fibrillation Ablation Procedures. Journal Of The American College Of Cardiology 2023, 81: 867-878. PMID: 36858707, DOI: 10.1016/j.jacc.2022.11.060.
• Rates and predictors of hospital and emergency department care after catheter ablation of atrial fibrillationFriedman D, Freeman J, Wong C, Febre J, Iglesias M, Khanna R, Piccini J. Rates and predictors of hospital and emergency department care after catheter ablation of atrial fibrillation. Journal Of Cardiovascular Electrophysiology 2023, 34: 823-830. PMID: 36738152, DOI: 10.1111/jce.15841.
• Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual WorkshopGo A, Al-Khatib S, Desvigne-Nickens P, Bansal N, Bushnell C, Fang M, Freeman J, Gage B, Hanke T, Hylek E, Lopes R, Noseworthy P, Reddy V, Singer D, Thomas K, Hills M, Turakhia M, Zieman S, Cooper L, Benjamin E. Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. Stroke 2023, 54: e75-e85. PMID: 36848427, PMCID: PMC9995163, DOI: 10.1161/strokeaha.121.038273.
• Device-Sizing and Associated Complications With Left Atrial Appendage Occlusion: Findings From the NCDR LAAO RegistrySandhu A, Varosy P, Du C, Aleong R, Tumolo A, West J, Tzou W, Curtis J, Freeman J, Friedman D, Hess P. Device-Sizing and Associated Complications With Left Atrial Appendage Occlusion: Findings From the NCDR LAAO Registry. Circulation Cardiovascular Interventions 2022, 15: e012183. PMID: 36472194, DOI: 10.1161/circinterventions.122.012183.
• Abstract 12203: Safety and Effectiveness of Pre-Procedure Imaging for Percutaneous Left Atrial Appendage Occlusion: Insights From the National Cardiovascular Data Registry (NCDR) LAAO RegistryClarke J, Higgins A, Wang Y, Faridi K, Curtis J, Freeman J, Friedman D. Abstract 12203: Safety and Effectiveness of Pre-Procedure Imaging for Percutaneous Left Atrial Appendage Occlusion: Insights From the National Cardiovascular Data Registry (NCDR) LAAO Registry. Circulation 2022, 146: a12203-a12203. DOI: 10.1161/circ.146.suppl_1.12203.
• Abstract 9599: Impact of Sex on Outcomes After WATCHMAN FLX ImplantationNair D, Piccini J, Hsu J, gibson D, Freeman J, Yeh R, Price M, Christen T, Allocco D, Kapadia S. Abstract 9599: Impact of Sex on Outcomes After WATCHMAN FLX Implantation. Circulation 2022, 146: a9599-a9599. DOI: 10.1161/circ.146.suppl_1.9599.
• Abstract 15360: Characteristics and In-Hospital Outcomes of Patients Undergoing Pulmonary Vein Isolation With and Without Adjunctive Lesions: Insights From the Ncdr Afib Ablation RegistryDarden D, Aldaas O, Du C, Feld G, Pothineni K, Gopinathannair R, Lakkireddy D, Curtis J, Freeman J, Akar J, Hsu J. Abstract 15360: Characteristics and In-Hospital Outcomes of Patients Undergoing Pulmonary Vein Isolation With and Without Adjunctive Lesions: Insights From the Ncdr Afib Ablation Registry. Circulation 2022, 146: a15360-a15360. DOI: 10.1161/circ.146.suppl_1.15360.
• Abstract 15068: Regional Variation in Atrial Fibrillation Ablation Care for Medicare Beneficiaries Across the United StatesHanna J, Freeman J, Hummel J, Curtis J, Lin Z, Akar J, Khera R. Abstract 15068: Regional Variation in Atrial Fibrillation Ablation Care for Medicare Beneficiaries Across the United States. Circulation 2022, 146: a15068-a15068. DOI: 10.1161/circ.146.suppl_1.15068.
• Comparative Safety of Transcatheter LAAO With the First-Generation Watchman and Next-Generation Watchman FLX DevicesPrice M, Friedman D, Du C, Wang Y, Lin Z, Curtis J, Freeman J. Comparative Safety of Transcatheter LAAO With the First-Generation Watchman and Next-Generation Watchman FLX Devices. JACC Cardiovascular Interventions 2022, 15: 2115-2123. PMID: 36357014, DOI: 10.1016/j.jcin.2022.09.002.
• Residual stroke risk despite oral anticoagulation in patients with atrial fibrillationCarlisle M, Shrader P, Fudim M, Pieper K, Blanco R, Fonarow G, Naccarelli G, Gersh B, Reiffel J, Kowey P, Steinberg B, Freeman J, Ezekowitz M, Singer D, Allen L, Chan P, Pokorney S, Peterson E, Piccini J, Patients and Investigators O. Residual stroke risk despite oral anticoagulation in patients with atrial fibrillation. Heart Rhythm O2 2022, 3: 621-628. PMID: 36589908, PMCID: PMC9795305, DOI: 10.1016/j.hroo.2022.09.018.
• Sex-based differences in atrial fibrillation ablation adverse eventsMszar R, Friedman D, Ong E, Du C, Wang Y, Zeitler E, Cunningham S, Akar J, Curtis J, Freeman J. Sex-based differences in atrial fibrillation ablation adverse events. Heart 2022, 109: 595-605. PMID: 36104219, DOI: 10.1136/heartjnl-2022-321192.
• Development and validation of an automated algorithm for end point adjudication for a large U.S. national registryFriedman DJ, Pierre D, Wang Y, Gambone L, Koutras C, Segawa C, Farb A, Vemulapalli S, Varosy PD, Masoudi FA, Lansky A, Curtis JP, Freeman JV. Development and validation of an automated algorithm for end point adjudication for a large U.S. national registry. American Heart Journal 2022, 254: 102-111. PMID: 36007567, DOI: 10.1016/j.ahj.2022.08.006.
• Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation : A Decision Analysis.Chew DS, Zhou K, Pokorney SD, Matchar DB, Vemulapalli S, Allen LA, Jackson KP, Samad Z, Patel MR, Freeman JV, Piccini JP. Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation : A Decision Analysis. Annals Of Internal Medicine 2022, 175: 1230-1239. PMID: 35969865, DOI: 10.7326/m21-4653.
• Abnormal left atrial body stiffness is predicted by appendage size: impact of appendage occlusion on left atrial mechanics assessed by pressure-volume analysisBregasi A, Freeman JV, Curtis JP, Akar JG, Ortiz-Leon XA, Maia JH, Higgins AY, Matthews RV, Sinusas AJ, McNamara RL, Sugeng L, Lin BA. Abnormal left atrial body stiffness is predicted by appendage size: impact of appendage occlusion on left atrial mechanics assessed by pressure-volume analysis. AJP Heart And Circulatory Physiology 2022, 323: h559-h568. PMID: 35960632, PMCID: PMC9576173, DOI: 10.1152/ajpheart.00083.2022.
• Indications for Left Atrial Appendage Occlusion in the United States and Associated In-Hospital Outcomes: Results From the NCDR LAAO RegistryDaimee UA, Wang Y, Masoudi FA, Varosy PD, Friedman DJ, Du C, Koutras C, Reddy VY, Saw J, Price MJ, Kusumoto FM, Curtis JP, Freeman JV. Indications for Left Atrial Appendage Occlusion in the United States and Associated In-Hospital Outcomes: Results From the NCDR LAAO Registry. Circulation Cardiovascular Quality And Outcomes 2022, 15: e008418. PMID: 35959677, PMCID: PMC9388561, DOI: 10.1161/circoutcomes.121.008418.
• PO-647-01 LEFT VENTRICULAR LEAD IMPLANTATION FAILURE: A REPORT FROM THE NATIONAL CARDIOVASCULAR DATA REGISTRYFriedman D, Freeman J, Singh J, Curtis J, Piccini J, Al-Khatib S, Jackson K. PO-647-01 LEFT VENTRICULAR LEAD IMPLANTATION FAILURE: A REPORT FROM THE NATIONAL CARDIOVASCULAR DATA REGISTRY. Heart Rhythm 2022, 19: s231. DOI: 10.1016/j.hrthm.2022.03.199.
• Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical TrialsFriedman DJ, Du C, Wang Y, Agarwal V, Varosy PD, Masoudi FA, Holmes DR, Reddy VY, Price MJ, Curtis JP, Freeman JV. Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials. JACC Cardiovascular Interventions 2022, 15: 950-961. PMID: 35512918, PMCID: PMC9370831, DOI: 10.1016/j.jcin.2022.02.029.
• Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial FibrillationFreeman JV, Higgins AY, Wang Y, Du C, Friedman DJ, Daimee UA, Minges KE, Pereira L, Goldsweig AM, Price MJ, Reddy VY, Gibson D, Doshi SK, Varosy PD, Masoudi FA, Curtis JP. Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation. Journal Of The American College Of Cardiology 2022, 79: 1785-1798. PMID: 35512858, PMCID: PMC9097170, DOI: 10.1016/j.jacc.2022.02.047.
• PO-634-05 RATES AND PREDICTORS OF HOSPITAL AND EMERGENCY DEPARTMENT CARE AFTER CATHETER ABLATION OF ATRIAL FIBRILLATIONFriedman D, Freeman J, Wong C, Febre J, Khanna R, Piccini J. PO-634-05 RATES AND PREDICTORS OF HOSPITAL AND EMERGENCY DEPARTMENT CARE AFTER CATHETER ABLATION OF ATRIAL FIBRILLATION. Heart Rhythm 2022, 19: s181. DOI: 10.1016/j.hrthm.2022.03.929.
• PO-656-04 SAFETY AND EFFECTIVENESS OF SAME DAY DISCHARGE AFTER LEFT ATRIAL APPENDAGE OCCLUSION WITH WATCHMAN FLXGibson D, Price M, Piccini J, Nair D, Hsu J, Freeman J, Yeh R, Christen T, Allocco D, Kapadia S. PO-656-04 SAFETY AND EFFECTIVENESS OF SAME DAY DISCHARGE AFTER LEFT ATRIAL APPENDAGE OCCLUSION WITH WATCHMAN FLX. Heart Rhythm 2022, 19: s268. DOI: 10.1016/j.hrthm.2022.03.283.
• Heart Rhythm Society Atrial Fibrillation Centers of Excellence Study: A survey analysis of stakeholder practices, needs, and barriersSandhu RK, Seiler A, Johnson CJ, Bunch TJ, Deering TF, Deneke T, Kirchhof P, Natale A, Piccini JP, Russo AM, Hills MT, Varosy PD, Araia A, Smith AM, Freeman J. Heart Rhythm Society Atrial Fibrillation Centers of Excellence Study: A survey analysis of stakeholder practices, needs, and barriers. Heart Rhythm 2022, 19: 1039-1048. PMID: 35428582, DOI: 10.1016/j.hrthm.2022.02.022.
• Clinical Impact of Residual Leaks Following Left Atrial Appendage Occlusion Insights From the NCDR LAAO RegistryAlkhouli M, Du C, Killu A, Simard T, Noseworthy PA, Friedman PA, Curtis JP, Freeman JV, Holmes DR. Clinical Impact of Residual Leaks Following Left Atrial Appendage Occlusion Insights From the NCDR LAAO Registry. JACC Clinical Electrophysiology 2022, 8: 766-778. PMID: 35387751, PMCID: PMC9233062, DOI: 10.1016/j.jacep.2022.03.001.
• Periprocedural Pericardial Effusion Complicating Transcatheter Left Atrial Appendage Occlusion: A Report From the NCDR LAAO RegistryPrice MJ, Valderrábano M, Zimmerman S, Friedman DJ, Kar S, Curtis JP, Masoudi FA, Freeman JV. Periprocedural Pericardial Effusion Complicating Transcatheter Left Atrial Appendage Occlusion: A Report From the NCDR LAAO Registry. Circulation Cardiovascular Interventions 2022, 15: e011718. PMID: 35369701, PMCID: PMC9132377, DOI: 10.1161/circinterventions.121.011718.
• Clinical Outcomes at 1 Year Following Transcatheter Left Atrial Appendage Occlusion in the United StatesPrice MJ, Slotwiner D, Du C, Freeman JV, Turi Z, Rammohan C, Kusumoto FM, Kavinsky C, Akar J, Varosy PD, Koutras C, Curtis JP, Masoudi FA. Clinical Outcomes at 1 Year Following Transcatheter Left Atrial Appendage Occlusion in the United States. JACC Cardiovascular Interventions 2022, 15: 741-750. PMID: 35393108, PMCID: PMC9116488, DOI: 10.1016/j.jcin.2022.02.009.
• To Occlude or Not to Occlude the Left Atrial Appendage in Women—ReplyDarden D, Freeman JV, Hsu JC. To Occlude or Not to Occlude the Left Atrial Appendage in Women—Reply. JAMA Cardiology 2022, 7: 464-465. PMID: 35171204, DOI: 10.1001/jamacardio.2021.5933.
• PERIPROCEDURAL PERICARDIAL EFFUSION COMPLICATING TRANSCATHETER LEFT ATRIAL APPENDAGE OCCLUSION: A REPORT FROM THE NCDR LAAO REGISTRYPrice M, Valderrabano M, Zimmerman S, Friedman D, Curtis J, Masoudi F, Freeman J. PERIPROCEDURAL PERICARDIAL EFFUSION COMPLICATING TRANSCATHETER LEFT ATRIAL APPENDAGE OCCLUSION: A REPORT FROM THE NCDR LAAO REGISTRY. Journal Of The American College Of Cardiology 2022, 79: 581. DOI: 10.1016/s0735-1097(22)01572-8.
• Longitudinal Outcomes of Subcutaneous or Transvenous Implantable Cardioverter-Defibrillators in Older PatientsFriedman DJ, Qin L, Parzynski C, Heist EK, Russo AM, Ranasinghe I, Zeitler EP, Minges KE, Akar JG, Freeman JV, Curtis JP, Al-Khatib SM. Longitudinal Outcomes of Subcutaneous or Transvenous Implantable Cardioverter-Defibrillators in Older Patients. Journal Of The American College Of Cardiology 2022, 79: 1050-1059. PMID: 35300816, DOI: 10.1016/j.jacc.2021.12.033.
• Changes in left atrial appendage orifice following percutaneous left atrial appendage closure using three-dimensional echocardiographyOrtiz-Leon XA, Posada-Martinez EL, Bregasi A, Chen W, Crandall I, Pereira J, Faridi KF, Akar JG, Lin BA, McNamara RL, Freeman JV, Curtis J, Arias-Godinez JA, Sugeng L. Changes in left atrial appendage orifice following percutaneous left atrial appendage closure using three-dimensional echocardiography. The International Journal Of Cardiovascular Imaging 2022, 38: 1361-1369. PMID: 35064846, DOI: 10.1007/s10554-022-02525-y.
• Heart Watch Study: protocol for a pragmatic randomised controlled trialDhruva SS, Shah ND, Vemulapalli S, Deshmukh A, Beatty AL, Gamble GM, Freeman JV, Hummel JP, Piccini JP, Akar JG, Ervin K, Arges KL, Emanuel L, Noseworthy PA, Hu T, Bartlett V, Ross JS. Heart Watch Study: protocol for a pragmatic randomised controlled trial. BMJ Open 2021, 11: e054550. PMID: 35234659, PMCID: PMC8719216, DOI: 10.1136/bmjopen-2021-054550.
• Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients with sarcoid cardiomyopathyHiggins AY, Annapureddy AR, Wang Y, Minges KE, Bellumkonda L, Lampert R, Rosenfeld LE, Jacoby DL, Curtis JP, Miller EJ, Freeman JV. Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients with sarcoid cardiomyopathy. American Heart Journal 2021, 246: 21-31. PMID: 34968442, DOI: 10.1016/j.ahj.2021.12.011.
• Change in hospitalization rates following transcatheter left atrial appendage occlusionMohammed M, Kattel S, Ahsan I, Samdani AJ, Chand S, Rai D, Bandyopadhyay D, Ranka S, Noheria A, Gupta SK, Sheldon SH, Rao M, Aronow WS, Freeman JV, Reddy M. Change in hospitalization rates following transcatheter left atrial appendage occlusion. Archives Of Medical Science - Atherosclerotic Diseases 2021, 6: e191-e195. PMID: 36161215, PMCID: PMC9487831, DOI: 10.5114/amsad.2021.111405.
• Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage OcclusionDarden D, Duong T, Du C, Munir MB, Han FT, Reeves R, Saw J, Zeitler EP, Al-Khatib SM, Russo AM, Minges KE, Curtis JP, Freeman JV, Hsu JC. Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion. JAMA Cardiology 2021, 6: 1275-1284. PMID: 34379072, PMCID: PMC8358791, DOI: 10.1001/jamacardio.2021.3021.
• Cannabis use disorder among atrial fibrillation admissions, 2008–2018Chouairi F, Miller PE, Guha A, Clarke J, Reinhardt SW, Ahmad T, Freeman JV, Desai NR, Friedman DJ. Cannabis use disorder among atrial fibrillation admissions, 2008–2018. Pacing And Clinical Electrophysiology 2021, 44: 1934-1938. PMID: 34506639, DOI: 10.1111/pace.14356.
• B-PO03-155 OUTCOMES OF LEFT ATRIAL APPENDAGE OCCLUSION WITH WATCHMAN IN CONTEMPORARY CLINICAL PRACTICE COMPARED WITH CLINICAL TRIALS: A POOLED ANALYSIS OF PROTECT-AF, PREVAIL, AND THE NCDR LAAO REGISTRYFriedman D, Du C, Agarwal Y, Varosy P, Masoudi F, Curtis J, Freeman J. B-PO03-155 OUTCOMES OF LEFT ATRIAL APPENDAGE OCCLUSION WITH WATCHMAN IN CONTEMPORARY CLINICAL PRACTICE COMPARED WITH CLINICAL TRIALS: A POOLED ANALYSIS OF PROTECT-AF, PREVAIL, AND THE NCDR LAAO REGISTRY. Heart Rhythm 2021, 18: s252. DOI: 10.1016/j.hrthm.2021.06.628.
• B-AB23-01 TEMPORAL TRENDS AND OUTCOMES AMONG CARDIAC RESYNCHRONIZATION THERAPY RECIPIENTS IN THE UNITED STATES, 2011-2015: INSIGHTS FROM THE NATIONAL CARDIOVASCULAR DATA REGISTRYDarden D, Xin X, Peterson P, Minges K, Birgersdotter-Green U, Freeman J, Curtis J, Hsu J. B-AB23-01 TEMPORAL TRENDS AND OUTCOMES AMONG CARDIAC RESYNCHRONIZATION THERAPY RECIPIENTS IN THE UNITED STATES, 2011-2015: INSIGHTS FROM THE NATIONAL CARDIOVASCULAR DATA REGISTRY. Heart Rhythm 2021, 18: s43-s44. DOI: 10.1016/j.hrthm.2021.06.128.
• National Trends in the Burden of Atrial Fibrillation During Hospital Admissions for Heart FailureReinhardt SW, Chouairi F, Miller PE, Clark KAA, Kay B, Fuery M, Guha A, Freeman JV, Ahmad T, Desai NR, Friedman DJ. National Trends in the Burden of Atrial Fibrillation During Hospital Admissions for Heart Failure. Journal Of The American Heart Association 2021, 10: e019412. PMID: 34013736, PMCID: PMC8483517, DOI: 10.1161/jaha.120.019412.
• Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT TrialChouairi F, Pacor J, Miller PE, Fuery MA, Caraballo C, Sen S, Leifer ES, Felker GM, Fiuzat M, O’Connor C, Januzzi JL, Friedman DJ, Desai NR, Ahmad T, Freeman JV. Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial. Mayo Clinic Proceedings Innovations Quality & Outcomes 2021, 5: 447-455. PMID: 33997640, PMCID: PMC8105522, DOI: 10.1016/j.mayocpiqo.2021.02.005.
• Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II)Jackson LR, Schrader P, Thomas L, Steinberg BA, Blanco R, Allen LA, Fonarow GC, Freeman JV, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J, Singer DE, Peterson ED, Piccini JP. Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II). American Journal Of Cardiovascular Drugs 2021, 21: 553-561. PMID: 33786798, DOI: 10.1007/s40256-021-00473-x.
• Relation of Cardiovascular Risk Factors to Mortality and Cardiovascular Events in Hospitalized Patients With Coronavirus Disease 2019 (from the Yale COVID-19 Cardiovascular Registry)Pareek M, Singh A, Vadlamani L, Eder M, Pacor J, Park J, Ghazizadeh Z, Heard A, Cruz-Solbes AS, Nikooie R, Gier C, Ahmed ZV, Freeman JV, Meadows J, Smolderen KGE, Lampert R, Velazquez EJ, Ahmad T, Desai NR. Relation of Cardiovascular Risk Factors to Mortality and Cardiovascular Events in Hospitalized Patients With Coronavirus Disease 2019 (from the Yale COVID-19 Cardiovascular Registry). The American Journal Of Cardiology 2021, 146: 99-106. PMID: 33539857, PMCID: PMC7849530, DOI: 10.1016/j.amjcard.2021.01.029.
• Abstract 12785: The American College of Cardiology's NCDR Afib Ablation Registry: A Summary of Initial Data Including Patient Characteristics, Procedural Characteristics, and Adverse EventsHsu J, Akar J, Marine J, Nichols S, Marcus G, Natale A, Noseworthy P, selzman K, Varosy P, Masoudi F, Du C, Freeman J, Curtis J, Kowey P. Abstract 12785: The American College of Cardiology's NCDR Afib Ablation Registry: A Summary of Initial Data Including Patient Characteristics, Procedural Characteristics, and Adverse Events. Circulation 2020, 142 DOI: 10.1161/circ.142.suppl_3.12785.
• Abstract 17419: Gender Differences in Outcomes With Patients Undergoing Percutaneous Left Atrial Appendage Occlusion: Insights From the NCDR LAAO RegistryDarden D, Duong T, Munir M, Han F, Reeves R, Du C, Wang Y, Minges K, Curtis J, Freeman J, Hsu J. Abstract 17419: Gender Differences in Outcomes With Patients Undergoing Percutaneous Left Atrial Appendage Occlusion: Insights From the NCDR LAAO Registry. Circulation 2020, 142 DOI: 10.1161/circ.142.suppl_3.17419.
• Abstract 16496: Longitudinal Outcomes After Implantation of a Subcutaneous or Transvenous Implantable Cardioverter Defibrillator in Older Patients: A Report From the National Cardiovascular Data RegistryFriedman D, Parzynski C, Heist E, Russo A, Ranasinghe I, Zeitler E, Minges K, Akar J, Freeman J, Curtis J, Al-khatib S. Abstract 16496: Longitudinal Outcomes After Implantation of a Subcutaneous or Transvenous Implantable Cardioverter Defibrillator in Older Patients: A Report From the National Cardiovascular Data Registry. Circulation 2020, 142 DOI: 10.1161/circ.142.suppl_3.16496.
• Abstract 16705: Prevalence and Outcomes Among Hospitalized Patients With Covid-19 and Atrial Fibrillation or FlutterGhazizadeh Z, Gier C, Singh A, Vadlamani L, Eder M, Pacor J, Park J, Pareek M, Ahmed Z, Smolderen K, Meadows J, Ahmad T, Desai N, Lampert R, Freeman J. Abstract 16705: Prevalence and Outcomes Among Hospitalized Patients With Covid-19 and Atrial Fibrillation or Flutter. Circulation 2020, 142 DOI: 10.1161/circ.142.suppl_3.16705.
• Mortality and readmission in non-ischemic compared with ischemic cardiomyopathies after implantable cardioverter-defibrillator implantationFreeman J, Bjerre J, Parzynski C, Minges K, Ahmad T, Desai N, Enriquez A, Spatz E, Friedman D, Curtis J, Hlatky M, Higgins A. Mortality and readmission in non-ischemic compared with ischemic cardiomyopathies after implantable cardioverter-defibrillator implantation. European Heart Journal 2020, 41 DOI: 10.1093/ehjci/ehaa946.0788.
• TCT CONNECT-449 Direct Oral Anticoagulants Versus Warfarin Following Left Atrial Appendage Occlusion: A Study-Level Meta-AnalysisJhand A, Thandra A, Aronow H, Freeman J, Sharma R, Coylewright M, Porter T, Goldsweig A. TCT CONNECT-449 Direct Oral Anticoagulants Versus Warfarin Following Left Atrial Appendage Occlusion: A Study-Level Meta-Analysis. Journal Of The American College Of Cardiology 2020, 76: b192. DOI: 10.1016/j.jacc.2020.09.477.
• Survival Following Implantable Cardioverter‐Defibrillator Implantation in Patients With Amyloid CardiomyopathyHiggins AY, Annapureddy AR, Wang Y, Minges KE, Lampert R, Rosenfeld LE, Jacoby DL, Curtis JP, Miller EJ, Freeman JV. Survival Following Implantable Cardioverter‐Defibrillator Implantation in Patients With Amyloid Cardiomyopathy. Journal Of The American Heart Association 2020, 9: e016038. PMID: 32867553, PMCID: PMC7726970, DOI: 10.1161/jaha.120.016038.
• Risk of COVID-19 infection after cardiac electrophysiology proceduresWorkman V, Freeman JV, Obasare ER, Jain S, Ganeshan R, Burr A, Blitzer M, Akar J, Lampert R. Risk of COVID-19 infection after cardiac electrophysiology procedures. Heart Rhythm O2 2020, 1: 239-242. PMID: 32904452, PMCID: PMC7455246, DOI: 10.1016/j.hroo.2020.08.006.
• Comparison of Mortality and Readmission in Non-Ischemic Versus Ischemic Cardiomyopathy After Implantable Cardioverter-Defibrillator ImplantationHiggins AY, Bjerre J, Parzynski CS, Minges KE, Ahmad T, Desai NR, Enriquez A, Spatz ES, Friedman DJ, Curtis JP, Hlatky MA, Freeman JV. Comparison of Mortality and Readmission in Non-Ischemic Versus Ischemic Cardiomyopathy After Implantable Cardioverter-Defibrillator Implantation. The American Journal Of Cardiology 2020, 133: 116-125. PMID: 32862971, DOI: 10.1016/j.amjcard.2020.07.035.
• Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF)Madhavan M, Holmes DN, Piccini JP, Freeman JV, Fonarow GC, Hylek EM, Kowey PR, Mahaffey KW, Pieper K, Peterson ED, Chan PS, Allen LA, Singer DE, Naccarelli GV, Reiffel JA, Steinberg BA, Gersh BJ, Investigators O. Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF). The American Journal Of Cardiology 2020, 132: 66-71. PMID: 32826041, DOI: 10.1016/j.amjcard.2020.07.006.
• Patterns of oral anticoagulation use with cardioversion in clinical practiceGeurink K, Holmes D, Ezekowitz MD, Pieper K, Fonarow G, Kowey PR, Reiffel JA, Singer DE, Freeman J, Gersh BJ, Mahaffey KW, Hylek EM, Naccarelli G, Piccini JP, Peterson ED, Pokorney SD. Patterns of oral anticoagulation use with cardioversion in clinical practice. Heart 2020, 107: 642-649. PMID: 32591363, DOI: 10.1136/heartjnl-2019-316315.
• The Use of the N + 1 Difference in Entrainment Mapping of Ventricular TachycardiaEnriquez A, Freeman J. The Use of the N + 1 Difference in Entrainment Mapping of Ventricular Tachycardia. 2020, 425-427. DOI: 10.1007/978-3-030-28533-3_102.
• Focal Atrial Tachycardia from the Non-Coronary CuspEnriquez A, Freeman J. Focal Atrial Tachycardia from the Non-Coronary Cusp. 2020, 281-284. DOI: 10.1007/978-3-030-28533-3_69.
• Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in PracticeSherwood MW, Piccini JP, Holmes DN, Pieper KS, Steinberg BA, Fonarow GC, Allen LA, Naccarelli GV, Kowey PR, Gersh BJ, Mahaffey KW, Singer DE, Ansell JE, Freeman JV, Chan PS, Reiffel JA, Blanco R, Peterson ED, Rao SV. Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice. Circulation Cardiovascular Interventions 2020, 13: e008274. PMID: 32408815, DOI: 10.1161/circinterventions.119.008274.
• Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisionsAli-Ahmed F, Pieper K, North R, Allen LA, Chan PS, Ezekowitz MD, Fonarow GC, Freeman JV, Go AS, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli GV, Pokorney SD, Reiffel JA, Singer DE, Steinberg BA, Peterson ED, Piccini JP, O’Brien E. Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisions. European Heart Journal - Quality Of Care And Clinical Outcomes 2020, 6: 263-272. PMID: 32392287, PMCID: PMC7778449, DOI: 10.1093/ehjqcco/qcaa040.
• Switching warfarin to direct oral anticoagulants in atrial fibrillation: Insights from the NCDR PINNACLE registrySciria CT, Maddox TM, Marzec L, Rodwin B, Virani SS, Annapureddy A, Freeman JV, O'Hare A, Liu Y, Song Y, Doros G, Zheng Y, Lee JJ, Daggubati R, Vadlamani L, Cannon C, Desai NR. Switching warfarin to direct oral anticoagulants in atrial fibrillation: Insights from the NCDR PINNACLE registry. Clinical Cardiology 2020, 43: 743-751. PMID: 32378265, PMCID: PMC7368350, DOI: 10.1002/clc.23376.
• Enhanced electrocardiographic monitoring of patients with Coronavirus Disease 2019Jain S, Workman V, Ganeshan R, Obasare ER, Burr A, DeBiasi RM, Freeman JV, Akar J, Lampert R, Rosenfeld LE. Enhanced electrocardiographic monitoring of patients with Coronavirus Disease 2019. Heart Rhythm 2020, 17: 1417-1422. PMID: 32387247, PMCID: PMC7200355, DOI: 10.1016/j.hrthm.2020.04.047.
• TT2 CARDIAC PERFORATION AMONG PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING ABLATION: WHAT ARE THE UNDERLYING PREDICTORS?Friedman D, Pokorney S, Ghanem A, Marcello S, Kalsekar I, Yadalam S, Akar J, Freeman J, Goldstein L, Khanna R, Piccini J. TT2 CARDIAC PERFORATION AMONG PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING ABLATION: WHAT ARE THE UNDERLYING PREDICTORS? Value In Health 2020, 23: s385-s386. DOI: 10.1016/j.jval.2020.04.1502.
• Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial FibrillationSteinberg BA, Holmes DN, Pieper K, Allen LA, Chan PS, Ezekowitz MD, Freeman JV, Fonarow GC, Gersh BJ, Hylek EM, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J, Singer DE, Peterson ED, Piccini JP, Mendelson R, Nahhas A, Neutel J, Padanilam B, Pan D, Poock J, Raffetto J, Greengold R, Roan P, Saba F, Sackett M, Schneider R, Seymour Z, Shanes J, Shoemaker J, Simms V, Smiley N, Smith D, Snipes C, Sotolongo R, Staniloae C, Stoltz S, Suresh D, Tak T, Tannenbaum A, Turk S, Vora K, Randhawa P, Zebrack J, Silva E, Riley E, Weinstein D, Vasiliauskas T, Goldbarg S, Hayward D, Yarlagadda C, Laurion D, Osunkoya A, Burns R, Castor T, Spiller D, Luttman C, Anton S, McGarvey J, Guthrie R, Deriso G, Flood R, Fleischer L, Fierstein J, Aggarwal R, Jacobs G, Adjei N, Akyea-Djamson A, Alfieri A, Bacon J, Bedwell N, Berger P, Berry J, Bhagwat R, Bloom S, Boccalandro F, Capo J, Kapadia S, Casanova R, Morriss III J, Christensen T, Elsen J, Farsad R, Fox D, Frandsen B, Gelernt M, Gill S, Grubb S, Hall C, Harris H, Hotchkiss D, Ip J, Jaffrani N, Jones A, Kazmierski J, Waxman F, Kneller G, Labroo A, Jaffe B, Lebenthal M, Lee D, Lillestol M, LeClerc K, Maccaro P, Mayer N, Kozlowski J, Benjamin S, Detweiler R, Igic P, Jackson T, Pappas J, Littlefield R, Frey A, Vranian R, Long W, Grena P, Arouni A, Quinn J, Browne K, Forman S, Ebinger M, Blonder R, Snyder H, Slabic S, Williams D, Stein R, Kirkland S, Cohen K, Walthall W, Davis K, Snoddy B, Alvarado O, Leach C, Rothman S, Sharma A, Olatidoye A, AlMahameed S, Rosenthal S, Sutter G, Reiter W, Thompson T, Thew S, Kobayashi J, Williams M, Kramer J, Latif S, Rhee B, Adler A, Ruiz-Serrano D, Stringam S, Wolok K, Focil A, Butman S, Ingersoll H, Borge R, Al-Saghir Y, Coats P, Farris N, Shore K, Schwartz M, Gornick C, Eilat P, Quinlan E, Paliwal Y, Mitra R, Jingo A, Aslam A, Watson R, Voyce S, Turakhia M, Goytia-Leos D, Lurie M, Mallis G, Atwater B, Strobel J, Murray J, Fisher D, Atieh M, Landes R, Drabick A, Harman E, Ashcraft B, Krista M, Videlefsky A, Rivera Zayas E, Tan A. Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation. Circulation Arrhythmia And Electrophysiology 2020, 13: e007775. PMID: 32298144, PMCID: PMC7247417, DOI: 10.1161/circep.119.007775.
• The NCDR Left Atrial Appendage Occlusion RegistryFreeman JV, Varosy P, Price MJ, Slotwiner D, Kusumoto FM, Rammohan C, Kavinsky CJ, Turi ZG, Akar J, Koutras C, Curtis JP, Masoudi FA. The NCDR Left Atrial Appendage Occlusion Registry. Journal Of The American College Of Cardiology 2020, 75: 1503-1518. PMID: 32238316, PMCID: PMC7205034, DOI: 10.1016/j.jacc.2019.12.040.
• Predictors of Cardiac Perforation With Catheter Ablation of Atrial FibrillationFriedman DJ, Pokorney SD, Ghanem A, Marcello S, Kalsekar I, Yadalam S, Akar JG, Freeman JV, Goldstein L, Khanna R, Piccini JP. Predictors of Cardiac Perforation With Catheter Ablation of Atrial Fibrillation. JACC Clinical Electrophysiology 2020, 6: 636-645. PMID: 32553212, DOI: 10.1016/j.jacep.2020.01.011.
• CHANGES OF LEFT ATRIAL APPENDAGE ORIFICE FOLLOWING PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE USING THREE-DIMENSIONAL ECHOCARDIOGRAPHYOrtiz-Leon X, Posada E, Chen W, Bregasi A, Crandall I, Pereira J, Miranda J, Akar J, Lin B, McNamara R, Freeman J, Curtis J, Arias-Godínez J, Sugeng L. CHANGES OF LEFT ATRIAL APPENDAGE ORIFICE FOLLOWING PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE USING THREE-DIMENSIONAL ECHOCARDIOGRAPHY. Journal Of The American College Of Cardiology 2020, 75: 1708. DOI: 10.1016/s0735-1097(20)32335-4.
• IMPACT OF PREOPERATIVE ATRIAL FIBRILLATION/FLUTTER IN LEFT VENTRICULAR ASSIST DEVICE RECIPIENTSClarke J, Caraballo C, Ravindra N, Miller P, McCullough M, Mezzacappa C, Mullan C, Lawrence J, Chouairi F, Desai N, Freeman J, Ahmad T, Friedman D. IMPACT OF PREOPERATIVE ATRIAL FIBRILLATION/FLUTTER IN LEFT VENTRICULAR ASSIST DEVICE RECIPIENTS. Journal Of The American College Of Cardiology 2020, 75: 982. DOI: 10.1016/s0735-1097(20)31609-0.
• Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillationInohara T, Holmes DN, Pieper K, Blanco RG, Allen LA, Fonarow GC, Gersh BJ, Hylek EM, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Mahaffey KW, Singer DE, Freeman JV, Steinberg BA, Peterson ED, Piccini JP. Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Heart 2020, 106: heartjnl-2019-315792. PMID: 31911503, DOI: 10.1136/heartjnl-2019-315792.
• Post–Emergency Department Atrial Fibrillation Clinics A Shifting Paradigm in Care? ∗Freeman JV, Ganeshan R. Post–Emergency Department Atrial Fibrillation Clinics A Shifting Paradigm in Care? ∗. JACC Clinical Electrophysiology 2020, 6: 53-55. PMID: 31971906, DOI: 10.1016/j.jacep.2019.10.006.
• Outcomes and Anticoagulation Use After Catheter Ablation for Atrial FibrillationFreeman JV, Shrader P, Pieper KS, Allen LA, Chan PS, Fonarow GC, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel JA, Singer DE, Go AS, Hylek EM, Steinberg BA, Peterson ED, Piccini JP. Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. Circulation Arrhythmia And Electrophysiology 2019, 12: e007612. PMID: 31830822, DOI: 10.1161/circep.119.007612.
• Comparison of Long-Term Adverse Outcomes in Patients With Atrial Fibrillation Having Ablation Versus Antiarrhythmic MedicationsFreeman JV, Tabada GH, Reynolds K, Sung SH, Singer DE, Wang PJ, Liu TI, Gupta N, Hlatky MA, Go AS. Comparison of Long-Term Adverse Outcomes in Patients With Atrial Fibrillation Having Ablation Versus Antiarrhythmic Medications. The American Journal Of Cardiology 2019, 125: 553-561. PMID: 31843233, PMCID: PMC6987016, DOI: 10.1016/j.amjcard.2019.11.004.
• Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillationLoring Z, Shrader P, Allen LA, Blanco R, Chan PS, Ezekowitz MD, Fonarow GC, Freeman JV, Gersh BJ, Mahaffey KW, Naccarelli GV, Pieper K, Reiffel JA, Singer DE, Steinberg BA, Thomas LE, Peterson ED, Piccini JP. Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. American Heart Journal 2019, 219: 21-30. PMID: 31710841, PMCID: PMC7285625, DOI: 10.1016/j.ahj.2019.10.008.
• Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillationPokorney SD, Holmes DN, Shrader P, Thomas L, Fonarow GC, Mahaffey KW, Gersh BJ, Kowey PR, Naccarelli GV, Freeman JV, Singer DE, Washam JB, Peterson ED, Piccini JP, Reiffel JA. Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. American Heart Journal 2019, 220: 145-154. PMID: 31812756, DOI: 10.1016/j.ahj.2019.09.017.
• Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial FibrillationPokorney SD, Holmes DN, Thomas L, Fonarow GC, Kowey PR, Reiffel JA, Singer DE, Freeman JV, Gersh BJ, Mahaffey KW, Hylek EM, Naccarelli GV, Ezekowitz MD, Piccini JP, Peterson ED. Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. JAMA Cardiology 2019, 4: 756-764. PMID: 31268487, PMCID: PMC6613340, DOI: 10.1001/jamacardio.2019.1960.
• Digoxin Use and Associated Adverse Events Among Older AdultsAngraal S, Nuti SV, Masoudi FA, Freeman JV, Murugiah K, Shah ND, Desai NR, Ranasinghe I, Wang Y, Krumholz HM. Digoxin Use and Associated Adverse Events Among Older Adults. The American Journal Of Medicine 2019, 132: 1191-1198. PMID: 31077654, DOI: 10.1016/j.amjmed.2019.04.022.
• Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation IIInohara T, Shrader P, Pieper K, Blanco RG, Allen LA, Fonarow GC, Gersh BJ, Go AS, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Mahaffey KW, Singer DE, Freeman JV, Steinberg BA, Peterson ED, Piccini JP, Patients and Investigators O. Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. American Heart Journal 2019, 213: 81-90. PMID: 31129441, DOI: 10.1016/j.ahj.2019.04.007.
• SURVIVAL FOLLOWING IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR IMPLANTATION IN PATIENTS WITH CARDIAC SARCOIDOSISHiggins A, Annapureddy A, Wang Y, Minges K, Lampert R, Rosenfeld L, Jacoby D, Curtis J, Miller E, Freeman J. SURVIVAL FOLLOWING IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR IMPLANTATION IN PATIENTS WITH CARDIAC SARCOIDOSIS. Journal Of The American College Of Cardiology 2019, 73: 306. DOI: 10.1016/s0735-1097(19)30914-3.
• SURVIVAL FOLLOWING IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR IMPLANTATION IN PATIENTS WITH CARDIAC AMYLOIDOSISHiggins A, Annapureddy A, Wang Y, Minges K, Lampert R, Rosenfeld L, Jacoby D, Curtis J, Miller E, Freeman J. SURVIVAL FOLLOWING IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR IMPLANTATION IN PATIENTS WITH CARDIAC AMYLOIDOSIS. Journal Of The American College Of Cardiology 2019, 73: 694. DOI: 10.1016/s0735-1097(19)31302-6.
• BUNDLE BRANCH REENTRANT VENTRICULAR TACHYCARDIA AFTER TRANSCATHETER AORTIC VALVE REPLACEMENTWorkman V, Freeman J, Forrest J, Upadhyaya K, Carney K, Enriquez A. BUNDLE BRANCH REENTRANT VENTRICULAR TACHYCARDIA AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT. Journal Of The American College Of Cardiology 2019, 73: 2934. DOI: 10.1016/s0735-1097(19)33540-5.
• NON VITAMIN K ORAL ANTICOAGULANTS ARE NOT ASSOCIATED WITH INCREASED RISK OF PERIOPERATIVE BLEEDING IN PATIENTS UNDERGOING CARDIAC SURGERYWaldron N, Shrader P, Levy J, Allen L, Chan P, Ezekowitz M, Fonarow G, Freeman J, Gersh B, Hylek E, Kowey P, Mahaffey K, Naccarelli G, Reiffel J, Singer D, Steinberg B, Peterson E, Piccini J. NON VITAMIN K ORAL ANTICOAGULANTS ARE NOT ASSOCIATED WITH INCREASED RISK OF PERIOPERATIVE BLEEDING IN PATIENTS UNDERGOING CARDIAC SURGERY. Journal Of The American College Of Cardiology 2019, 73: 547. DOI: 10.1016/s0735-1097(19)31155-6.
• THE IMPACT OF TEMPORARY INTERRUPTIONS OF WARFARIN ON DOWNSTREAM TIME IN THERAPEUTIC RANGE IN PATIENTS WITH ATRIAL FIBRILLATION: RESULTS FROM ORBIT AFMadhavan M, Holmes D, Piccini J, Freeman J, Fonarow G, Hylek E, Kowey P, Mahaffey K, Pieper K, Peterson E, Chan P, Allen L, Singer D, Naccarelli G, Reiffel J, Steinberg B, Gersh B. THE IMPACT OF TEMPORARY INTERRUPTIONS OF WARFARIN ON DOWNSTREAM TIME IN THERAPEUTIC RANGE IN PATIENTS WITH ATRIAL FIBRILLATION: RESULTS FROM ORBIT AF. Journal Of The American College Of Cardiology 2019, 73: 468. DOI: 10.1016/s0735-1097(19)31076-9.
• CHARACTERISTICS OF AF PATIENTS WITH LARGE IMPROVEMENT IN SYMPTOMS AT ONE YEAR: SUPER-RESPONSE IN THE ORBIT-AF REGISTRYSteinberg B, Holmes D, Pieper K, Chan P, Fonarow G, Freeman J, Allen L, Hylek E, Ezekowitz M, Kowey P, Singer D, Gersh B, Mahaffey K, Naccarelli G, Reiffel J, Peterson E, Piccini J. CHARACTERISTICS OF AF PATIENTS WITH LARGE IMPROVEMENT IN SYMPTOMS AT ONE YEAR: SUPER-RESPONSE IN THE ORBIT-AF REGISTRY. Journal Of The American College Of Cardiology 2019, 73: 436. DOI: 10.1016/s0735-1097(19)31044-7.
• ASSOCIATION BETWEEN GUIDELINE-DIRECTED MEDICAL THERAPIES FOR COMORBID CONDITIONS AND CLINICAL OUTCOMES AMONG INDIVIDUALS WITH ATRIAL FIBRILLATIONLoring Z, Shrader P, Allen L, Blanco R, Chan P, Ezekowitz M, Fonarow G, Freeman J, Gersh B, Mahaffey K, Naccarelli G, Pieper K, Reiffel J, Singer D, Steinberg B, Peterson E, Piccini J. ASSOCIATION BETWEEN GUIDELINE-DIRECTED MEDICAL THERAPIES FOR COMORBID CONDITIONS AND CLINICAL OUTCOMES AMONG INDIVIDUALS WITH ATRIAL FIBRILLATION. Journal Of The American College Of Cardiology 2019, 73: 476. DOI: 10.1016/s0735-1097(19)31084-8.
• Abstract WP403: Factors Associated With Patient-Reported Shared Decision-Making for Stroke Prevention in Atrial FibrillationO'Brien E, Pieper K, Thiem R, Fonarow G, Kowey P, Chan P, Freeman J, Naccarelli G, Mahaffey K, Ezekowitz M, Go A, Gersh B, Singer D, Reiffel J, Piccini J. Abstract WP403: Factors Associated With Patient-Reported Shared Decision-Making for Stroke Prevention in Atrial Fibrillation. Stroke 2019, 50 DOI: 10.1161/str.50.suppl_1.wp403.
• Can advanced analytics fix modern medicine's problem of uncertainty, imprecision, and inaccuracy?Ahmad T, Freeman JV, Asselbergs FW. Can advanced analytics fix modern medicine's problem of uncertainty, imprecision, and inaccuracy? European Journal Of Heart Failure 2018, 21: 86-89. PMID: 30537243, DOI: 10.1002/ejhf.1370.
• Atrial Fibrillation Thermographic and Endoscopic Monitoring of Patients: Safety Algorithm for the EsophagusHummel JP, Kadado AJ, Baker M, Gehi AK, Mounsey JP, Sadaf MI, Enriquez AD, Freeman JV, Akar JG. Atrial Fibrillation Thermographic and Endoscopic Monitoring of Patients: Safety Algorithm for the Esophagus. Circulation Arrhythmia And Electrophysiology 2018, 11: e006814. PMID: 30562101, DOI: 10.1161/circep.118.006814.
• Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II.Essien UR, Holmes DN, Jackson LR, Fonarow GC, Mahaffey KW, Reiffel JA, Steinberg BA, Allen LA, Chan PS, Freeman JV, Blanco RG, Pieper KS, Piccini JP, Peterson ED, Singer DE. Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II. JAMA Cardiology 2018, 3: 1174-1182. PMID: 30484833, PMCID: PMC6583087, DOI: 10.1001/jamacardio.2018.3945.
• B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillationInohara T, Kim S, Pieper K, Blanco RG, Allen LA, Fonarow GC, Gersh BJ, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Mahaffey KW, Singer DE, Freeman JV, Steinberg BA, Peterson ED, Piccini JP. B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. Heart 2018, 105: 370. PMID: 30228248, DOI: 10.1136/heartjnl-2018-313642.
• Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AFWasham JB, Holmes DN, Thomas LE, Pokorney SD, Hylek EM, Fonarow GC, Mahaffey KW, Gersh BJ, Kowey PR, Ansell JE, Go AS, Reiffel JA, Freeman JV, Singer DE, Naccarelli G, Blanco R, Peterson ED, Piccini JP. Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF. Journal Of The American Heart Association 2018, 7: e008928. PMID: 30371218, PMCID: PMC6222961, DOI: 10.1161/jaha.118.008928.
• Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial FibrillationO'Brien EC, Holmes DN, Thomas LE, Fonarow GC, Allen LA, Gersh BJ, Kowey PR, Singer DE, Ezekowitz MD, Naccarelli GV, Ansell JE, Chan PS, Mahaffey KW, Go AS, Freeman JV, Reiffel JA, Peterson ED, Piccini JP, Hylek EM. Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. Circulation 2018, 138: 889-897. PMID: 29678813, DOI: 10.1161/circulationaha.117.031354.
• Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA2DS2‐VASc Scores: Findings From the ORBIT‐AF I and II RegistriesJackson L, Kim S, Fonarow GC, Freeman JV, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Singer D, Thomas L, Blanco R, Peterson ED, Piccini J, Patients and Investigators T. Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA2DS2‐VASc Scores: Findings From the ORBIT‐AF I and II Registries. Journal Of The American Heart Association 2018, 7: e008764. PMID: 30369317, PMCID: PMC6201408, DOI: 10.1161/jaha.118.008764.
• Response to: “Enlisting Emergency Medicine Clinicians to Help Reduce Strokes in High‐Risk Patients With Atrial Fibrillation and Flutter”Hsu JC, Freeman JV. Response to: “Enlisting Emergency Medicine Clinicians to Help Reduce Strokes in High‐Risk Patients With Atrial Fibrillation and Flutter”. Clinical Pharmacology & Therapeutics 2018, 104: 615-615. PMID: 30006932, DOI: 10.1002/cpt.1143.
• Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillationDurheim MT, Holmes DN, Blanco RG, Allen LA, Chan PS, Freeman JV, Fonarow GC, Go AS, Hylek EM, Mahaffey KW, Pokorney SD, Reiffel JA, Singer DE, Peterson ED, Piccini JP. Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. Heart 2018, 104: 1850. PMID: 29875139, DOI: 10.1136/heartjnl-2017-312735.
• ASSOCIATION BETWEEN ELEVATED B-TYPE NATRIURETIC PEPTIDE, DISEASE PROGRESSION, AND CLINICAL OUTCOMES AMONG PATIENTS WITH ATRIAL FIBRILLATIONInohara T, Kim S, Pieper K, Blanco R, Allen L, Fonarow G, Gersh B, Ezekowitz M, Kowey P, Reiffel J, Naccarelli G, Chan P, Mahaffey K, Singer D, Freeman J, Steinberg B, Peterson E, Piccini J. ASSOCIATION BETWEEN ELEVATED B-TYPE NATRIURETIC PEPTIDE, DISEASE PROGRESSION, AND CLINICAL OUTCOMES AMONG PATIENTS WITH ATRIAL FIBRILLATION. Journal Of The American College Of Cardiology 2018, 71: a507. DOI: 10.1016/s0735-1097(18)31048-9.
• Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter DefibrillatorFriedman DJ, Parzynski CS, Heist EK, Russo AM, Akar JG, Freeman JV, Curtis JP, Al-Khatib SM. Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator. Circulation 2018, 137: 2463-2477. PMID: 29463509, PMCID: PMC5988932, DOI: 10.1161/circulationaha.117.032167.
• Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)Steinberg BA, Shrader P, Pieper K, Thomas L, Allen LA, Ansell J, Chan PS, Ezekowitz MD, Fonarow GC, Freeman JV, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli GV, Reiffel JA, Singer DE, Peterson ED, Piccini JP, Investigators T. Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). Journal Of The American Heart Association 2018, 7: e007633. PMID: 29453305, PMCID: PMC5850192, DOI: 10.1161/jaha.117.007633.
• Underuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary ReviewHsu JC, Freeman JV. Underuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary Review. Clinical Pharmacology & Therapeutics 2018, 104: 301-310. PMID: 29328506, DOI: 10.1002/cpt.1024.
• Remote monitoring of implantable cardiac devicesGaneshan R, Enriquez AD, Freeman JV. Remote monitoring of implantable cardiac devices. Current Opinion In Cardiology 2018, 33: 20-30. PMID: 29059076, DOI: 10.1097/hco.0000000000000471.
• Postoperative Atrial Fibrillation and Maslow’s HammerKadado AJ, Freeman J, Akar JG. Postoperative Atrial Fibrillation and Maslow’s Hammer. Anesthesia & Analgesia 2018, 126: 19-20. PMID: 29252478, DOI: 10.1213/ane.0000000000002414.
• Association of Atrial Fibrillation Clinical Phenotypes with Treatment Patterns and Outcomes: A Multicenter Registry StudyInohara T, Shrader P, Pieper K, Blanco RG, Thomas L, Singer DE, Freeman JV, Allen LA, Fonarow GC, Gersh B, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Steinberg BA, Peterson ED, Piccini JP. Association of Atrial Fibrillation Clinical Phenotypes with Treatment Patterns and Outcomes: A Multicenter Registry Study. JAMA Cardiology 2018, 3: 54-63. PMID: 29128866, PMCID: PMC5833527, DOI: 10.1001/jamacardio.2017.4665.
• Contemporary Procedural Complications, Hospitalizations, and Emergency Visits After Catheter Ablation for Atrial FibrillationFreeman JV, Tabada GH, Reynolds K, Sung SH, Liu TI, Gupta N, Go AS. Contemporary Procedural Complications, Hospitalizations, and Emergency Visits After Catheter Ablation for Atrial Fibrillation. The American Journal Of Cardiology 2017, 121: 602-608. PMID: 29331355, PMCID: PMC5805603, DOI: 10.1016/j.amjcard.2017.11.034.
• Abstract 20924: Threshold Based Infrared Imaging for Prevention of Esophageal Thermal Injury During Atrial Fibrillation AblationHummel J, Kadado A, Baker M, Sadaf M, Gehi A, Bhatt P, Enriquez A, Freeman J, Marieb M, Mounsey P, Akar J. Abstract 20924: Threshold Based Infrared Imaging for Prevention of Esophageal Thermal Injury During Atrial Fibrillation Ablation. Circulation 2017, 136 DOI: 10.1161/circ.136.suppl_1.20924.
• Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society GuidelinesBarnett AS, Kim S, Fonarow GC, Thomas LE, Reiffel JA, Allen LA, Freeman JV, Naccarelli G, Mahaffey KW, Go AS, Kowey PR, Ansell JE, Gersh BJ, Hylek EM, Peterson ED, Piccini JP. Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines. Circulation Arrhythmia And Electrophysiology 2017, 10: e005051. PMID: 29141842, DOI: 10.1161/circep.117.005051.
• Long-term morbidity and mortality after implantable cardioverter-defibrillator implantation with procedural complication: A report from the National Cardiovascular Data RegistryKipp R, Hsu JC, Freeman J, Curtis J, Bao H, Hoffmayer KS. Long-term morbidity and mortality after implantable cardioverter-defibrillator implantation with procedural complication: A report from the National Cardiovascular Data Registry. Heart Rhythm 2017, 15: 847-854. PMID: 28987459, DOI: 10.1016/j.hrthm.2017.09.043.
• Disease understanding in patients newly diagnosed with atrial fibrillationKaufman BG, Kim S, Pieper K, Allen LA, Gersh BJ, Naccarelli GV, Ezekowitz MD, Fonarow GC, Mahaffey KW, Singer DE, Chan PS, Freeman JV, Ansell J, Kowey PR, Rieffel JA, Piccini J, Peterson E, O'Brien EC. Disease understanding in patients newly diagnosed with atrial fibrillation. Heart 2017, 104: 494. PMID: 28790169, PMCID: PMC5861387, DOI: 10.1136/heartjnl-2017-311800.
• Can machine learning complement traditional medical device surveillance? A case-study of dual-chamber implantable cardioverter–defibrillatorsRoss JS, Bates J, Parzynski CS, Akar JG, Curtis JP, Desai NR, Freeman JV, Gamble GM, Kuntz R, Li SX, Marinac-Dabic D, Masoudi FA, Normand ST, Ranasinghe I, Shaw RE, Krumholz HM. Can machine learning complement traditional medical device surveillance? A case-study of dual-chamber implantable cardioverter–defibrillators. Medical Devices Evidence And Research 2017, 10: 165-188. PMID: 28860874, PMCID: PMC5566316, DOI: 10.2147/mder.s138158.
• Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantationBlack‐Maier E, Kim S, Steinberg BA, Fonarow GC, Freeman JV, Kowey PR, Ansell J, Gersh BJ, Mahaffey KW, Naccarelli G, Hylek EM, Go AS, Peterson ED, Piccini JP, Investigators F. Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. Clinical Cardiology 2017, 40: 746-751. PMID: 28543401, PMCID: PMC5638096, DOI: 10.1002/clc.22726.
• NUISANCE BLEEDING IN ANTICOAGULATED PATIENTS WITH ATRIAL FIBRILLATION: INSIGHTS FROM THE OUTCOMES REGISTRY FOR BETTER INFORMED TREATMENT OF ATRIAL FIBRILLATION (ORBIT-AF)O'Brien E, Simon D, Thomas L, Singer D, Kowey P, Naccarelli G, Fonarow G, Reiffel J, Ansell J, Go A, Chan P, Ezekowitz M, Gersh B, Allen L, Freeman J, Mahaffey K, Piccini J, Peterson E, Hylek E. NUISANCE BLEEDING IN ANTICOAGULATED PATIENTS WITH ATRIAL FIBRILLATION: INSIGHTS FROM THE OUTCOMES REGISTRY FOR BETTER INFORMED TREATMENT OF ATRIAL FIBRILLATION (ORBIT-AF). Journal Of The American College Of Cardiology 2017, 69: 536. DOI: 10.1016/s0735-1097(17)33925-6.
• Abstract 057: Understanding of Treatment Strategies Among Patients Newly Diagnosed With Atrial Fibrillation: Findings From SATELITTEKaufman B, Kim S, Pieper K, Ezekowitz M, Fonarow G, Naccarelli G, Mahaffey K, Ansell J, Berger P, Reiffel J, Chan P, Singer D, Allen L, Freeman J, Kowey P, Gersh B, Piccini J, Peterson E, O’Brien E. Abstract 057: Understanding of Treatment Strategies Among Patients Newly Diagnosed With Atrial Fibrillation: Findings From SATELITTE. Circulation Cardiovascular Quality And Outcomes 2017, 10 DOI: 10.1161/circoutcomes.10.suppl_3.057.
• National Trends in Atrial Fibrillation Hospitalization, Readmission, and Mortality for Medicare Beneficiaries, 1999–2013Freeman JV, Wang Y, Akar J, Desai N, Krumholz H. National Trends in Atrial Fibrillation Hospitalization, Readmission, and Mortality for Medicare Beneficiaries, 1999–2013. Circulation 2017, 135: 1227-1239. PMID: 28148599, DOI: 10.1161/circulationaha.116.022388.
• Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial FibrillationHess PL, Kim S, Fonarow GC, Thomas L, Singer DE, Freeman JV, Gersh BJ, Ansell J, Kowey PR, Mahaffey KW, Chan PS, Steinberg BA, Peterson ED, Piccini JP, Patients and Investigators O. Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. The American Journal Of Medicine 2016, 130: 449-456. PMID: 27888051, DOI: 10.1016/j.amjmed.2016.11.001.
• Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAILFreeman JV, Hutton DW, Barnes GD, Zhu RP, Owens DK, Garber AM, Go AS, Hlatky MA, Heidenreich PA, Wang PJ, Al-Ahmad A, Turakhia MP. Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. Circulation Arrhythmia And Electrophysiology 2016, 9: e003407. PMID: 27307517, PMCID: PMC4911813, DOI: 10.1161/circep.115.003407.
• Long-Term Risk for Device-Related Complications and Reoperations After Implantable Cardioverter-Defibrillator Implantation: An Observational Cohort Study.Ranasinghe I, Parzynski CS, Freeman JV, Dreyer RP, Ross JS, Akar JG, Krumholz HM, Curtis JP. Long-Term Risk for Device-Related Complications and Reoperations After Implantable Cardioverter-Defibrillator Implantation: An Observational Cohort Study. Annals Of Internal Medicine 2016, 165: 20-29. PMID: 27135392, DOI: 10.7326/m15-2732.
• TREATMENT AND STROKE RISK IN LOW RISK CHA2DS2VASC ATRIAL FIBRILLATION PATIENTS: FINDINGS FROM THE ORBIT-AF REGISTRYJackson L, Kim S, Ansell J, Fonarow G, Freeman J, Gersh B, Go A, Hylek E, Kowey P, Mahaffey K, Singer D, Thomas L, Peterson E, Piccini J. TREATMENT AND STROKE RISK IN LOW RISK CHA2DS2VASC ATRIAL FIBRILLATION PATIENTS: FINDINGS FROM THE ORBIT-AF REGISTRY. Journal Of The American College Of Cardiology 2016, 67: 788. DOI: 10.1016/s0735-1097(16)30789-6.
• Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT‐AF RegistryJackson LR, Kim SH, Piccini JP, Gersh BJ, Naccarelli GV, Reiffel JA, Freeman J, Thomas L, Chang P, Fonarow GC, Go AS, Mahaffey KW, Peterson ED, Kowey PR. Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT‐AF Registry. Clinical Cardiology 2015, 39: 119-125. PMID: 26720750, PMCID: PMC4784163, DOI: 10.1002/clc.22504.
• Abstract 16076: Cost-effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF vs. PREVAILFreeman J, Hutton D, Barnes G, Zhu R, Owens D, Garber A, Go A, Hlatky M, Heidenreich P, Wang P, Al-Ahmad A, Turakhia M. Abstract 16076: Cost-effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF vs. PREVAIL. Circulation 2015, 132 DOI: 10.1161/circ.132.suppl_3.16076.
• Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient OutcomesFreeman JV, Simon DN, Go AS, Spertus J, Fonarow GC, Gersh BJ, Hylek EM, Kowey PR, Mahaffey KW, Thomas LE, Chang P, Peterson ED, Piccini JP. Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes. Circulation Cardiovascular Quality And Outcomes 2015, 8: 393-402. PMID: 26058720, DOI: 10.1161/circoutcomes.114.001303.
• Remote Monitoring and Outcomes in Pacemaker and Defibrillator Patients Big Data Saving Lives?∗Freeman JV, Saxon L. Remote Monitoring and Outcomes in Pacemaker and Defibrillator Patients Big Data Saving Lives?∗. Journal Of The American College Of Cardiology 2015, 65: 2611-2613. PMID: 25983010, DOI: 10.1016/j.jacc.2015.04.031.
• Abstract 236: Trends in Hospitalization for Digoxin Toxicity and Subsequent Outcomes Among Medicare Beneficiaries in the United States, 1999-2011Nuti S, Masoudi F, Freeman J, Murugiah K, Desai N, Ranasinghe I, Shah N, Wang Y, Krumholz H. Abstract 236: Trends in Hospitalization for Digoxin Toxicity and Subsequent Outcomes Among Medicare Beneficiaries in the United States, 1999-2011. Circulation Cardiovascular Quality And Outcomes 2015, 8 DOI: 10.1161/circoutcomes.8.suppl_2.236.
• Feasibility of Extended Ambulatory Electrocardiogram Monitoring to Identify Silent Atrial Fibrillation in High‐risk Patients: The Screening Study for Undiagnosed Atrial Fibrillation (STUDY‐AF)Turakhia MP, Ullal AJ, Hoang DD, Than CT, Miller JD, Friday KJ, Perez MV, Freeman JV, Wang PJ, Heidenreich PA. Feasibility of Extended Ambulatory Electrocardiogram Monitoring to Identify Silent Atrial Fibrillation in High‐risk Patients: The Screening Study for Undiagnosed Atrial Fibrillation (STUDY‐AF). Clinical Cardiology 2015, 38: 285-292. PMID: 25873476, PMCID: PMC4654330, DOI: 10.1002/clc.22387.
• Heart rate is associated with progression of atrial fibrillation, independent of rhythmHolmqvist F, Kim S, Steinberg BA, Reiffel JA, Mahaffey KW, Gersh BJ, Fonarow GC, Naccarelli GV, Chang P, Freeman JV, Kowey PR, Thomas L, Peterson ED, Piccini JP. Heart rate is associated with progression of atrial fibrillation, independent of rhythm. Heart 2015, 101: 894. PMID: 25732748, PMCID: PMC4453487, DOI: 10.1136/heartjnl-2014-307043.
• Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation—Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)Holmqvist F, Guan N, Zhu Z, Kowey PR, Allen LA, Fonarow GC, Hylek EM, Mahaffey KW, Freeman JV, Chang P, Holmes DN, Peterson ED, Piccini JP, Gersh BJ, Investigators O. Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation—Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal 2015, 169: 647-654.e2. PMID: 25965712, DOI: 10.1016/j.ahj.2014.12.024.
• Abstract 20158: Long-Term Device-Related Adverse Events After Implantable Cardioverter-Defibrillator TherapyRanasinghe I, Parzynski C, Freeman J, Dreyer R, Ross J, Akar J, Krumholz H, Curtis J. Abstract 20158: Long-Term Device-Related Adverse Events After Implantable Cardioverter-Defibrillator Therapy. Circulation 2014, 130 DOI: 10.1161/circ.130.suppl_2.20158.
• Abstract 18703: Impact of the 2014 Atrial Fibrillation Guideline on the Proportion of Patients Recommended for Oral AnticoagulationO’Brien E, Kim S, Hess P, Freeman J, Thomas L, Fonarow G, Ansell J, Kowey P, Hylek E, Mahaffey K, Chang P, Piccini J, Peterson E. Abstract 18703: Impact of the 2014 Atrial Fibrillation Guideline on the Proportion of Patients Recommended for Oral Anticoagulation. Circulation 2014, 130 DOI: 10.1161/circ.130.suppl_2.18703.
• Abstract 15680: Sinus Node Dysfunction in Associated With Higher Symptom Burden and Increased Risk of Progression to Permanent Atrial Fibrillation: Results From ORBIT-AF RegistryJackson L, Kim S, Piccini J, Gersh B, Naccarelli G, Reiffel J, Freeman J, Thomas L, Chang P, Fonarow G, Go A, Mahaffey K, Peterson E, Kowey P. Abstract 15680: Sinus Node Dysfunction in Associated With Higher Symptom Burden and Increased Risk of Progression to Permanent Atrial Fibrillation: Results From ORBIT-AF Registry. Circulation 2014, 130 DOI: 10.1161/circ.130.suppl_2.15680.
• Digoxin and Risk of Death in Adults With Atrial FibrillationFreeman JV, Reynolds K, Fang M, Udaltsova N, Steimle A, Pomernacki NK, Borowsky LH, Harrison TN, Singer DE, Go AS. Digoxin and Risk of Death in Adults With Atrial Fibrillation. Circulation Arrhythmia And Electrophysiology 2014, 8: 49-58. PMID: 25414270, PMCID: PMC4334705, DOI: 10.1161/circep.114.002292.
• Effectiveness and Safety of Digoxin Among Contemporary Adults With Incident Systolic Heart FailureFreeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and Safety of Digoxin Among Contemporary Adults With Incident Systolic Heart Failure. Circulation Cardiovascular Quality And Outcomes 2013, 6: 525-533. PMID: 24021697, DOI: 10.1161/circoutcomes.111.000079.
• Use of Evidence-based Cardiac Prevention Therapy Among Outpatients with Atrial FibrillationHess PL, Kim S, Piccini JP, Allen LA, Ansell JE, Chang P, Freeman JV, Gersh BJ, Kowey PR, Mahaffey KW, Thomas L, Peterson ED, Fonarow GC. Use of Evidence-based Cardiac Prevention Therapy Among Outpatients with Atrial Fibrillation. The American Journal Of Medicine 2013, 126: 625-632.e1. PMID: 23787195, PMCID: PMC4037289, DOI: 10.1016/j.amjmed.2013.01.037.
• DIGOXIN AND RISK OF DEATH IN ADULTS WITH ATRIAL FIBRILLATION: THE ATRIA-CVRN STUDYFreeman J, Reynolds K, Fang M, Udaltsova N, Steimle A, Singer D, Go A. DIGOXIN AND RISK OF DEATH IN ADULTS WITH ATRIAL FIBRILLATION: THE ATRIA-CVRN STUDY. Journal Of The American College Of Cardiology 2013, 61: e262. DOI: 10.1016/s0735-1097(13)60262-4.
• Effectiveness of β-Blockers in Heart Failure With Left Ventricular Systolic Dysfunction and Chronic Kidney DiseaseChang TI, Yang J, Freeman JV, Hlatky MA, Go AS. Effectiveness of β-Blockers in Heart Failure With Left Ventricular Systolic Dysfunction and Chronic Kidney Disease. Journal Of Cardiac Failure 2013, 19: 176-182. PMID: 23482078, PMCID: PMC4126798, DOI: 10.1016/j.cardfail.2013.01.006.
• Effectiveness of Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy in Heart FailureFreeman JV, Masoudi FA. Effectiveness of Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy in Heart Failure. Heart Failure Clinics 2012, 9: 59-77. PMID: 23168318, DOI: 10.1016/j.hfc.2012.09.006.
• Abstract 112: Use of Evidence-Based Therapies in the Treatment of Cardiovascular Comorbidities and Risk Factors in Patients with Atrial Fibrillation: Findings From the ORBIT-AF RegistryHess P, Kim S, Piccini J, Chang P, Allen L, Gersh B, Ansell J, Hylek E, Mahaffey K, Freeman J, Go A, Peterson E, Fonarow G. Abstract 112: Use of Evidence-Based Therapies in the Treatment of Cardiovascular Comorbidities and Risk Factors in Patients with Atrial Fibrillation: Findings From the ORBIT-AF Registry. Circulation Cardiovascular Quality And Outcomes 2012, 5 DOI: 10.1161/circoutcomes.5.suppl_1.a112.
• Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillationSolomon MD, Ullal AJ, Hoang DD, Freeman JV, Heidenreich P, Turakhia MP. Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation. Journal Of Cardiovascular Medicine 2012, 13: 86-96. PMID: 22193838, DOI: 10.2459/jcm.0b013e32834f23cf.
• Procedural Complications, Rehospitalizations, and Repeat Procedures After Catheter Ablation for Atrial FibrillationShah RU, Freeman JV, Shilane D, Wang PJ, Go AS, Hlatky MA. Procedural Complications, Rehospitalizations, and Repeat Procedures After Catheter Ablation for Atrial Fibrillation. Journal Of The American College Of Cardiology 2012, 59: 143-149. PMID: 22222078, PMCID: PMC5340189, DOI: 10.1016/j.jacc.2011.08.068.
• Physician Procedure Volume and Complications of Cardioverter-Defibrillator ImplantationFreeman JV, Wang Y, Curtis JP, Heidenreich PA, Hlatky MA. Physician Procedure Volume and Complications of Cardioverter-Defibrillator Implantation. Circulation 2011, 125: 57-64. PMID: 22095828, DOI: 10.1161/circulationaha.111.046995.
• Cost-effectiveness of Implantable Cardioverter-Defibrillators and Cardiac Resynchronization TherapyFreeman J, Ullal A, Turakhia M. Cost-effectiveness of Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy. Cardiac Electrophysiology Clinics 2011, 3: 421-440. DOI: 10.1016/j.ccep.2011.05.008.
• The Impact of ST Elevation on Athletic ScreeningLeo T, Uberoi A, Jain NA, Garza D, Chowdhury S, Freeman JV, Perez M, Ashley E, Froelicher V. The Impact of ST Elevation on Athletic Screening. Clinical Journal Of Sport Medicine 2011, 21: 433-440. PMID: 21892017, DOI: 10.1097/jsm.0b013e31822cf105.
• Interpretation of the Electrocardiogram of Young AthletesUberoi A, Stein R, Perez MV, Freeman J, Wheeler M, Dewey F, Peidro R, Hadley D, Drezner J, Sharma S, Pelliccia A, Corrado D, Niebauer J, Estes NA, Ashley E, Froelicher V. Interpretation of the Electrocardiogram of Young Athletes. Circulation 2011, 124: 746-757. PMID: 21824936, DOI: 10.1161/circulationaha.110.013078.
• Is Less More? Dual- Versus Single-Chamber Implantable Cardioverter-Defibrillators⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.Al-Ahmad A, Freeman JV. Is Less More? Dual- Versus Single-Chamber Implantable Cardioverter-Defibrillators⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology. Journal Of The American College Of Cardiology 2011, 58: 1014-1015. PMID: 21867835, DOI: 10.1016/j.jacc.2011.05.032.
• Dabigatran Compared With Warfarin for Stroke Prevention in Atrial FibrillationFreeman J, Turakhia M. Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation. Annals Of Internal Medicine 2011, 154: 570. DOI: 10.7326/0003-4819-154-8-201104190-00014.
• MOLECULAR AUTOPSY FOR SUDDEN CARDIAC DEATH USING WHOLE GENOME SEQUENCINGDewey F, Wheeler M, Cordero S, Perez M, Pavlovic A, Pushkarev D, Freeman J, Quake S, Ashley E. MOLECULAR AUTOPSY FOR SUDDEN CARDIAC DEATH USING WHOLE GENOME SEQUENCING. Journal Of The American College Of Cardiology 2011, 57: e1159. DOI: 10.1016/s0735-1097(11)61159-5.
• ReplyFreeman J, Wang Y, Curtis J, Heidenreich P, Hlatky M. Reply. Journal Of The American College Of Cardiology 2011, 57: 1714. DOI: 10.1016/j.jacc.2010.12.023.
• Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Annals Of Internal Medicine 2010, 154: 1-11. PMID: 21041570, DOI: 10.7326/0003-4819-154-1-201101040-00289.
• The Relation Between Hospital Procedure Volume and Complications of Cardioverter-Defibrillator Implantation From the Implantable Cardioverter-Defibrillator RegistryFreeman JV, Wang Y, Curtis JP, Heidenreich PA, Hlatky MA. The Relation Between Hospital Procedure Volume and Complications of Cardioverter-Defibrillator Implantation From the Implantable Cardioverter-Defibrillator Registry. Journal Of The American College Of Cardiology 2010, 56: 1133-1139. PMID: 20863954, DOI: 10.1016/j.jacc.2010.07.007.
• THE RELATION BETWEEN HOSPITAL PROCEDURE VOLUME AND COMPLICATIONS OF CARDIOVERTER-DEFIBRILLATOR IMPLANTATION FROM THE NATIONAL CARDIOVASCULAR DATA REGISTRYFreeman J, Wang Y, Curtis J, Heidenreich P, Hlatky M. THE RELATION BETWEEN HOSPITAL PROCEDURE VOLUME AND COMPLICATIONS OF CARDIOVERTER-DEFIBRILLATOR IMPLANTATION FROM THE NATIONAL CARDIOVASCULAR DATA REGISTRY. Journal Of The American College Of Cardiology 2010, 55: a129.e1205. DOI: 10.1016/s0735-1097(10)61206-5.
• Adding an Electrocardiogram to the Pre-participation Examination in Competitive Athletes: A Systematic ReviewPerez M, Fonda H, Le VV, Mitiku T, Ray J, Freeman JV, Ashley E, Froelicher VF. Adding an Electrocardiogram to the Pre-participation Examination in Competitive Athletes: A Systematic Review. Current Problems In Cardiology 2009, 34: 586-662. PMID: 19887232, DOI: 10.1016/j.cpcardiol.2009.08.002.
• The ageing athlete: screening prior to vigorous exertion in asymptomatic adults without known cardiovascular diseaseFreeman J, Froelicher V, Ashley E. The ageing athlete: screening prior to vigorous exertion in asymptomatic adults without known cardiovascular disease. British Journal Of Sports Medicine 2009, 43: 696. PMID: 19734505, DOI: 10.1136/bjsm.2008.054783.
• Should the exercise ECG be used to screen for sudden cardiac death?Freeman J, Ashley EA, Froelicher V. Should the exercise ECG be used to screen for sudden cardiac death? European Heart Journal 2009, 30: 528-529. PMID: 19201762, DOI: 10.1093/eurheartj/ehp029.
• Statin Use and Ventricular Arrhythmias During Clinical Treadmill TestingDEWEY FE, PEREZ M, HADLEY D, FREEMAN JV, WANG P, ASHLEY EA, MYERS J, FROELICHER VF. Statin Use and Ventricular Arrhythmias During Clinical Treadmill Testing. Journal Of Cardiovascular Electrophysiology 2009, 20: 193-199. PMID: 18775041, DOI: 10.1111/j.1540-8167.2008.01284.x.
• Prediction of Cardiovascular Death using a Novel Heart Rate Recovery ParameterHADLEY DM, DEWEY FE, FREEMAN JV, MYERS JN, FROELICHER VF. Prediction of Cardiovascular Death using a Novel Heart Rate Recovery Parameter. Medicine & Science In Sports & Exercise 2008, 40: 1072-1079. PMID: 18460999, DOI: 10.1249/mss.0b013e318167665a.
• Response to “Heart rate variability is dependent on the level of heart rate” by Nieminen et alDewey F, Freeman J, Engel G, Oviedo R, Abrol N, Ahmed N, Myers J, Froelicher V. Response to “Heart rate variability is dependent on the level of heart rate” by Nieminen et al. American Heart Journal 2007, 154: e15. DOI: 10.1016/j.ahj.2007.04.049.
• Novel predictor of prognosis from exercise stress testing: Heart rate variability response to the exercise treadmill testDewey FE, Freeman JV, Engel G, Oviedo R, Abrol N, Ahmed N, Myers J, Froelicher VF. Novel predictor of prognosis from exercise stress testing: Heart rate variability response to the exercise treadmill test. American Heart Journal 2007, 153: 281-288. PMID: 17239690, DOI: 10.1016/j.ahj.2006.11.001.
• P3-32 Integrated exercise induced temporal and spectral heart rate variability is a powerful prognostic marker for cardiovascular deathHadley D, Freeman J, Dewey F, Engel G, Froelicher V. P3-32 Integrated exercise induced temporal and spectral heart rate variability is a powerful prognostic marker for cardiovascular death. Heart Rhythm 2006, 3: s188. DOI: 10.1016/j.hrthm.2006.02.564.
• AB50-3 A novel and independent heart rate recovery parameter prognostic for cardiovascular deathHadley D, Freeman J, Dewey F, Engel G, Froelicher V. AB50-3 A novel and independent heart rate recovery parameter prognostic for cardiovascular death. Heart Rhythm 2006, 3: s104. DOI: 10.1016/j.hrthm.2006.02.314.
• Autonomic Nervous System Interaction With the Cardiovascular System During ExerciseFreeman JV, Dewey FE, Hadley DM, Myers J, Froelicher VF. Autonomic Nervous System Interaction With the Cardiovascular System During Exercise. Progress In Cardiovascular Diseases 2006, 48: 342-362. PMID: 16627049, DOI: 10.1016/j.pcad.2005.11.003.
• Evaluation of neonatal verbal autopsy using physician review versus algorithm-based cause-of-death assignment in rural Nepal.Freeman JV, Christian P, Khatry SK, Adhikari RK, LeClerq SC, Katz J, Darmstadt GL. Evaluation of neonatal verbal autopsy using physician review versus algorithm-based cause-of-death assignment in rural Nepal. Paediatric And Perinatal Epidemiology 2005, 19: 323-31. PMID: 15958155, DOI: 10.1111/j.1365-3016.2005.00652.x.